RecruitingNot ApplicableNCT05248620

Prophylactic Antibiotic Treatment in Hemodialysis

Prophylactic Antibiotic Treatment in End Stage Kidney Disease and Central Venous Catheter as Hemodialysis Vascular Access

Sponsor

Zealand University Hospital

Enrollment

800 participants

Start Date

Feb 14, 2022

Study Type

INTERVENTIONAL

Conditions

Hemodialysis

Summary

The purpose of this study is to assess the efficacy of prophylactic antibiotic treatment on blood stream infections and severe culture negative infections, in patients on newly started hemodialysis(HD), with a central venous catheter as vascular access.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

End Stage Kidney Disease (ESKD) patients who receive an uncuffed or cuffed CVC for expected chronic HD, regardless of previous ESKD treatment modality (PD or KTX) and hemodialysis access (AV-fistula or AV-graft))
≥18 years
Ability to understand the study background, risk and benefit of treatment and to give written informed consent

Exclusion Criteria5

Unable to give informed consent
Known intolerance to beta-lactam antibiotics and clindamycin
Active infection treated with antibiotics
Breastfeeding
Pregnancy. In women of childbearing age, an approved birth control must be ensured at least 1 month before and during all the 6 months of antibiotic/placebo treatment.

Interested in this trial?

Get notified about updates and connect with the research team.